Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
| ▸ | SCN1A | P35498 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.47 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.47 |
| ▸ | BCHE | P06276 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1206593 | 0.88 | MAPT (0.78) | MAPTHRH3CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL11778606 | 0.87 | MAPT (0.76) | MAPT | |
| SCHEMBL19300121 | 0.84 | MAPT (0.72) | MAPTHRH3LMNACYP1A2CHRM2 | |
| SCHEMBL11780095 | 0.84 | MAPT (0.71) | MAPT | |
| SCHEMBL16421915 | 0.83 | MAPT (0.71) | MAPTHRH3BCHEKDM4EALDH1A1 | |
| SCHEMBL7130261 | 0.83 | MAPT (0.70) | MAPTHRH3KCNH2 | |
| SCHEMBL7932030 | 0.82 | MAPT (0.70) | MAPTLMNACYP1A2CHRM2CYP3A4 | |
| SCHEMBL28783183 | 0.82 | MAPT (0.69) | MAPTHRH3KCNH2BCHEKDM4E | |
| SCHEMBL9166930 | 0.81 | MAPT (0.68) | MAPTHRH3KCNH2 | |
| SCHEMBL7120513 | 0.81 | MAPT (0.68) | MAPTHRH3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020190774-A1 | NOVEL SMALL MOLECULE INHIBITORS OF TEAD TRANSCRIPTION FACTORS | THE GENERAL HOSPITAL CORPORATION (US) | 2020-09-24 | — | — | WO | disclosed |
| US-9902740-B2 | Macrocyclic benzodiazepine dimers, conjugates thereof, preparation and uses | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-02-27 | — | — | US | disclosed |
| US-20170260205-A1 | MACROCYCLIC BENZODIAZEPINE DIMERS, CONJUGATES THEREOF, PREPARATION AND USES | BRISTOL-MYERS SQUIBB COMPANY | 2017-09-14 | — | — | US | disclosed |
| US-9688694-B2 | Macrocyclic benzodiazepine dimers, conjugates thereof, preparation and uses | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-06-27 | — | — | US | disclosed |
| US-20160376288-A1 | MACROCYCLIC BENZODIAZEPINE DIMERS, CONJUGATES THEREOF, PREPARATION AND USES | BRISTOL-MYERS SQUIBB COMPANY | 2016-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170260205-A1 | MACROCYCLIC BENZODIAZEPINE DIMERS, CONJUGATES THEREOF, PREPARATION AND USES | GABRA1, GABRA2, GABRA3 | MAPT 1534/4885HRH3 560/4885LMNA 2469/4885 |
| US-20160376288-A1 | MACROCYCLIC BENZODIAZEPINE DIMERS, CONJUGATES THEREOF, PREPARATION AND USES | GABRA1, GABRA2, GABRA3 | MAPT 1534/4885HRH3 560/4885LMNA 2469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.